

Future treatment options for progressive MS

J. Chataway

University College London, London, United Kingdom

There is a need to build on the success of anti-inflammatory strategies in Progressive MS (PMS). They are only partially effective and do not address neuro-protective and remyelinating aspects of a complex disease process. This talk will use recently reported trials at phase 2 and 3, to illustrate what compounds have or have not shown a signature and to consider the implications of these results. It will also present a forward look to molecules currently in trial and the planned time horizons.

Disclosure

In the last 3 years, JC has received support from the Efficacy and Evaluation (EME) Programme, a Medical Research Council (MRC) and National Institute for Health Research (NIHR) partnership and the Health Technology Assessment (HTA) Programme (NIHR), the UK MS Society, the US National MS Society and the Rosetrees Trust. He is supported in part by the National Institute for Health Research, University College London Hospitals, Biomedical Research Centre, London, UK. He has been a local principal investigator for a trial in MS funded by the Canadian MS society. A local principal investigator for commercial trials funded by: Actelion, Biogen, Novartis and Roche; has received an investigator grant from Novartis; and has taken part in advisory boards/consultancy for Azadyne, Biogen, Celgene, Janssen, MedDay, Merck, Novartis and Roche.